Clinical Trial Update: ERCC1 Targeted Trial [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating an ERCC1-targeted therapy for lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: University College, London | Conditions: Lung Cancer | Phase 3 | Status: TERMINATED